Amgen Launches Assistance Program for NSCLC Biomarker Testing

On April 19, 2021, Amgen announced its launch of Biomarker Assist^TM—a program to help patients with metastatic non-small cell lung cancer (NSCLC) gain access to biomarker testing. Through this new program, eligible patients may save on costs related to biomarker testing. 

Learn more about Biomarker Assist^TM on its website.

Read the Amgen announcement.

Posted 4/19/2021